Coherus Biosciences | CHRS - Gewinn Vor Steuern

Aktienkurs
1.68
Täglich Wechseln
0.03 1.82%
Monatlich
-5.62%
Jährlich
100.98%
Q2 Prognose
1.63




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Baxter International USD 121M 12M 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Fujifilm JPY 100.28B 10.32B 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Merck USD 6.74B 22M 2025-09
Myriad Genetics USD 4.6M 3.4M 2025-12
Pacira USD 9.52M 11.45M 2025-09
Perrigo USD 22.4M 19.2M 2025-09
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Teva Pharmaceutical Industries USD 91M 555M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09
Xencor USD -4.27M 1.76M 2025-12
Zoetis USD 887M 15M 2025-09